Nuvectis Pharma, Inc. (NASDAQ:NVCT) stock is trading lower after the company reported data from the Phase 1b study evaluating ...

Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate.

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

Nuvectis Pharma (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

Michael J. Carson, Vice President of Finance at Nuvectis Pharma, Inc. (NASDAQ:NVCT), recently sold a portion of his holdings in the company. According to a recent SEC filing, Carson sold 2,755 ...

In a recent move that signals confidence in Nuvectis Pharma, Inc. (NASDAQ:NVCT), CEO and Chairman Ron Bentsur has increased his stake in the company through the purchase of ...

The stock price of Nuvectis Pharma Inc (NASDAQ: NVCT) has jumped by 29.62 compared to previous close of 8.34. Despite this, the company has seen a gain of 68.64% in its stock price over the last five ...

Investing.com – United States equities were lower at the close on Thursday, as losses in the Dow Jones Industrials, Dow Jones ...

U.S. stocks were lower after the close on Thursday, as losses in the Industrials, Healthcare and Consumer Goods sectors led ...